Overactive Bladder PGx

The Overactive Bladder PGx Panel is intended for individuals receiving treatment for overactive bladder or lower urinary tract symptoms who may benefit from personalized pharmacogenetic-guided medication management. This panel evaluates clinically relevant genetic variants associated with drug metabolism, efficacy, and tolerability for medications commonly used in the management of overactive bladder symptoms, including urinary urgency, frequency, and incontinence. Pharmacogenetic testing may help guide medication selection and dosing, reduce the risk of adverse drug reactions, and support safer, more effective individualized treatment strategies. Upon completion of testing, patients receive an interpretive pharmacogenetic report and certificate summarizing clinically relevant results and medication-related findings to support ongoing care and future treatment decisions.

Turnaround Time: 3-7 business days
Preferred specimens: Saliva
Alternate specimens: Buccal Swab

Testing Kit Request Form

Therapies for overactive bladder, including anticholinergics and beta-3 agonists, may have variable efficacy and tolerability among patients. Genetic differences affecting drug metabolism and receptor sensitivity may contribute to these differences. Pharmacogenomic testing can help inform treatment selection and improve symptom management while minimizing side effects.